Aprea Therapeutics, Inc.
APRE
$0.80
-$0.04-4.32%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 5.10K | 123.20K | 285.70K | 488.20K | 841.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.10K | 123.20K | 285.70K | 488.20K | 841.00K |
| Cost of Revenue | 6.72M | 6.17M | 7.04M | 8.39M | 9.60M |
| Gross Profit | -6.72M | -6.05M | -6.76M | -7.91M | -8.76M |
| SG&A Expenses | 6.51M | 6.53M | 6.48M | 5.91M | 6.04M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.23M | 12.70M | 13.52M | 14.31M | 15.64M |
| Operating Income | -13.22M | -12.58M | -13.23M | -13.82M | -14.80M |
| Income Before Tax | -12.31M | -11.95M | -12.60M | -13.04M | -13.85M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.31 | -11.95 | -12.60 | -13.04 | -13.85 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.31M | -11.95M | -12.60M | -13.04M | -13.85M |
| EBIT | -13.22M | -12.58M | -13.23M | -13.82M | -14.80M |
| EBITDA | -13.20M | -12.56M | -13.21M | -13.80M | -14.77M |
| EPS Basic | -1.08 | -1.54 | -1.97 | -2.14 | -2.31 |
| Normalized Basic EPS | -0.67 | -0.96 | -1.23 | -1.34 | -1.44 |
| EPS Diluted | -1.08 | -1.54 | -1.97 | -2.14 | -2.31 |
| Normalized Diluted EPS | -0.67 | -0.96 | -1.23 | -1.34 | -1.44 |
| Average Basic Shares Outstanding | 82.23M | 34.83M | 26.14M | 24.40M | 23.97M |
| Average Diluted Shares Outstanding | 82.23M | 34.83M | 26.14M | 24.40M | 23.97M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |